Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Metrics to compare | 2185 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2185PeersSector | |
---|---|---|---|---|
P/E Ratio | −10.5x | −30.9x | −0.5x | |
PEG Ratio | −0.21 | −0.55 | 0.00 | |
Price/Book | 1.4x | 2.6x | 2.6x | |
Price / LTM Sales | - | 7.6x | 3.3x | |
Upside (Analyst Target) | - | 9.3% | 43.3% | |
Fair Value Upside | Unlock | −10.6% | 6.9% | Unlock |